Background: Bosentan is an oral dual endothelin receptor antagonist, which has been proven to be efficacious for preventing new digital ulcers in patients with systemic sclerosis (SSc) by two high quality randomized controlled trials. However, its efficacy for non-digital ulcers in SSc has still remained unknown.
Objective: To evaluate the efficacy of bosentan on non-digital ulcers in patients with SSc.
Methods: Bosentan was administered against 5 SSc patients with pulmonary arterial hypertension, who also had non-digital ulcers refractory to conventional treatments. The efficacy of bosentan on non-digital ulcers and its association with ...
Effects of bosentan on non-digital ulcers in patients with systemic sclerosis is a post from: Skincare
Effects of bosentan on non-digital ulcers in patients with systemic sclerosis via BuzzBlazer.com
No comments:
Post a Comment